Juan Justo Quintas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juan Justo Quintas has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Aalya Hamouda
Department of Surgery, Division of Urology McGill University Montreal Quebec Canada
1 shared publicationAdel Arezki
Department of Surgery, Division of Urology McGill University Montreal Quebec Canada
1 shared publication- Agustín Fraile
ROC Clinic Direction, Martínez Campos 17, 28010 Madrid, Spain
1 shared publication - Alexander P. Glaser
Division of Urology NorthShore University Health System Evanston IL USA
1 shared publication - Anouk Leathead
Faculty of Medicine University of Montreal Montreal QC Canada
1 shared publication - Berta Miró
Bioinformatics and Statistical Unit, Vall d’Hebron Research Institute, 08035 Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by Elsevier in Urology Video Journal
- Vol. 32
Simultaneous step-by-step comparison of four robotic platforms in radical prostatectomy: da Vinci Xi, da Vinci SP, Hugo™ RAS, and TOUMAI®
- 24 September 2026
- Published by Elsevier in Urology Video Journal
- Vol. 32
Open AccessSimultaneous step-by-step comparison of four robotic platforms in radical prostatectomy: da Vinci Xi, da Vinci SP, Hugo™ RAS, and TOUMAI®
- Open Access
External Validation and Clinical Impact of the Barcelona Predictive Models for Detecting Significant Prostate Cancer in Prostate Biopsies in an Ibero-American Population
Objectives: To externally validate the Barcelona Predictive Models (BCN-PM 1 and 2) for detecting csPCa in an Ibero-American population. BCN-PM 1 was designed to reduce magnetic resonance imaging (MRI) use, whereas BCN-PM 2 aims to decrease unnecessary prostate biopsies. Methods: This prospective, multicenter study included 661 men with suspected PCa recruited in 2025 across three Ibero-American centers. All participants underwent MRI followed by targeted biopsies of lesions with the Prostate Imaging–Reporting and Data System (PI-RADS) ≥ 3, along with systematic biopsy. When PI-RADS lesions were p < 0.001). Decision curve analysis demonstrated a net benefit for both models compared with strategies of biopsy in all or no men. BCN-PM 2 showed greater net benefit than BCN-PM 1. At 95% sensitivity, BCN-PM 1 reduced MRI requests by 10.6%, while BCN-PM 2 avoided 19.4% of unnecessary biopsies. The sequential use of BCN-PM 1 and 2 resulted in a 10.6% reduction in MRI exams and a 23.1% reduction in biopsies, at the cost of missing 8.4% of csPCa cases. The performance of the biopsy improved from 53.7% to 64.0% (p < 0.001). Conclusions: BCN-PM1 and BCN-PM 2 were successfully validated in an Ibero-American population.
Open AccessExternal Validation and Clinical Impact of the Barcelona Predictive Models for Detecting Significant Prostate Cancer in Prostate Biopsies in an Ibero-American Population
Objectives: To externally validate the Barcelona Predictive Models (BCN-PM 1 and 2) for detecting csPCa in an Ibero-American population. BCN-PM 1 was designed to reduce magnetic resonance imaging (MRI) use, whereas BCN-PM 2 aims to decrease unnecessary prostate biopsies. Methods: This prospective, multicenter study included 661 men with suspected PCa recruited in 2025 across three Ibero-American centers. All participants underwent MRI followed by targeted biopsies of lesions with the Prostate Imaging–Reporting and Data System (PI-RADS) ≥ 3, along with systematic biopsy. When PI-RADS lesions were p < 0.001). Decision curve analysis demonstrated a net benefit for both models compared with strategies of biopsy in all or no men. BCN-PM 2 showed greater net benefit than BCN-PM 1. At 95% sensitivity, BCN-PM 1 reduced MRI requests by 10.6%, while BCN-PM 2 avoided 19.4% of unnecessary biopsies. The sequential use of BCN-PM 1 and 2 resulted in a 10.6% reduction in MRI exams and a 23.1% reduction in biopsies, at the cost of missing 8.4% of csPCa cases. The performance of the biopsy improved from 53.7% to 64.0% (p < 0.001). Conclusions: BCN-PM1 and BCN-PM 2 were successfully validated in an Ibero-American population.
- Open Access
- 30 January 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (2)
Outcomes of Aquablation in BPH with bladder stones: Analysis of the ICARUS database
Objective: The purpose of this study is investigate the clinical outcomes of men with benign prostatic hyperplasia (BPH) and bladder stones treated concomitantly with Aquablation and bladder stone removal in an international, multi‐institutional cohort. Patients and Methods: We performed a retrospective analysis of men who underwent Aquablation between 2018 and 2024. Patients were divided into two cohorts: men with bladder stones and those without. Outcomes assessed included baseline demographics and variables (medication use, prostate volume, prior BPH surgery), operative characteristics (OR time, transfusion requirement, complications), and functional outcomes were measured by the International Prostate Symptom Score (IPSS), peak urinary flow rate ( Q max ) and PVR at regular intervals over 24 months. Results: A total of 1885 men were analysed, including 60 men with bladder stones and 1825 without. Patients with bladder stones had higher rates of prior BPH surgery (15% vs. 5.5%, p = 0.015) and pre‐operative urinary retention (28.3% vs. 14.8%, p = 0.004) as well as larger prostate volumes (98.6 ml vs. 77 ml, p < 0.0001). Total operative time was longer in the bladder stone group (76.5 mins vs. 55.0 mins, p < 0.001), but there were no significant differences in Aquablation time or bleeding complications including transfusions. There was also no difference in improvements in IPSS, Q max and PVR post‐operatively. Conclusion: This study demonstrates that Aquablation is safe and effective in the management of BPH regardless of concomitant bladder stone treatment.
- 30 January 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (2)
Open AccessOutcomes of Aquablation in BPH with bladder stones: Analysis of the ICARUS database
Objective: The purpose of this study is investigate the clinical outcomes of men with benign prostatic hyperplasia (BPH) and bladder stones treated concomitantly with Aquablation and bladder stone removal in an international, multi‐institutional cohort. Patients and Methods: We performed a retrospective analysis of men who underwent Aquablation between 2018 and 2024. Patients were divided into two cohorts: men with bladder stones and those without. Outcomes assessed included baseline demographics and variables (medication use, prostate volume, prior BPH surgery), operative characteristics (OR time, transfusion requirement, complications), and functional outcomes were measured by the International Prostate Symptom Score (IPSS), peak urinary flow rate ( Q max ) and PVR at regular intervals over 24 months. Results: A total of 1885 men were analysed, including 60 men with bladder stones and 1825 without. Patients with bladder stones had higher rates of prior BPH surgery (15% vs. 5.5%, p = 0.015) and pre‐operative urinary retention (28.3% vs. 14.8%, p = 0.004) as well as larger prostate volumes (98.6 ml vs. 77 ml, p < 0.0001). Total operative time was longer in the bladder stone group (76.5 mins vs. 55.0 mins, p < 0.001), but there were no significant differences in Aquablation time or bleeding complications including transfusions. There was also no difference in improvements in IPSS, Q max and PVR post‐operatively. Conclusion: This study demonstrates that Aquablation is safe and effective in the management of BPH regardless of concomitant bladder stone treatment.
- 21 April 2025
- Published by Elsevier in European Urology Focus
- Vol. 11 (4) , 564-567
Phytotherapy for the Treatment of Lower Urinary Tract Symptoms: Current Position and Unmet Needs
- 21 April 2025
- Published by Elsevier in European Urology Focus
- Vol. 11 (4) , 564-567
Phytotherapy for the Treatment of Lower Urinary Tract Symptoms: Current Position and Unmet Needs
- Open Access
Organ-Sparing Surgery for Testicular Germ Cell Tumors: A Current Perspective
Background and Objectives: We aimed to evaluate the oncological and functional outcomes of organ-sparing surgery for testicular germ cell tumors, a procedure that seeks to strike a balance between effective cancer control and organ preservation, in the treatment of testicular tumors. We aimed to discuss the surgical technique and complications, and determine the appropriate candidate selection for this approach. Material and Methods: A comprehensive literature search was conducted to identify relevant studies on organ-sparing surgery for testicular tumors. Various databases, including PubMed, Embase, and Cochrane Library, were used. Studies reporting on surgical techniques, complications, and oncologic and functional outcomes were included for analysis. Results: Current evidence suggests that organ-sparing surgery for testicular germ cell tumors can be considered a safe and efficacious alternative to radical orchiectomy. The procedure is associated with adequate oncological control, as indicated by low recurrence rates and low complication rates. Endocrine testicular function can be preserved in around 80–90% of patients and paternity can be achieved in approximately half of the patients. Candidate selection for this surgery is typically based on the following criteria: pre-surgery normal levels of testosterone and luteinizing hormone, synchronous or metachronous bilateral tumors, tumor in a solitary testis, and tumor size less than 50% of the testis. Conclusions: Organ-sparing surgery for testicular germ cell tumors offers a promising approach that balances oncological control and preservation of testicular function. Further research, including large-scale prospective studies and long-term follow-ups, is warranted to validate the effectiveness and durability of organ-sparing surgery and to identify optimal patient selection criteria.
Open AccessOrgan-Sparing Surgery for Testicular Germ Cell Tumors: A Current Perspective
Background and Objectives: We aimed to evaluate the oncological and functional outcomes of organ-sparing surgery for testicular germ cell tumors, a procedure that seeks to strike a balance between effective cancer control and organ preservation, in the treatment of testicular tumors. We aimed to discuss the surgical technique and complications, and determine the appropriate candidate selection for this approach. Material and Methods: A comprehensive literature search was conducted to identify relevant studies on organ-sparing surgery for testicular tumors. Various databases, including PubMed, Embase, and Cochrane Library, were used. Studies reporting on surgical techniques, complications, and oncologic and functional outcomes were included for analysis. Results: Current evidence suggests that organ-sparing surgery for testicular germ cell tumors can be considered a safe and efficacious alternative to radical orchiectomy. The procedure is associated with adequate oncological control, as indicated by low recurrence rates and low complication rates. Endocrine testicular function can be preserved in around 80–90% of patients and paternity can be achieved in approximately half of the patients. Candidate selection for this surgery is typically based on the following criteria: pre-surgery normal levels of testosterone and luteinizing hormone, synchronous or metachronous bilateral tumors, tumor in a solitary testis, and tumor size less than 50% of the testis. Conclusions: Organ-sparing surgery for testicular germ cell tumors offers a promising approach that balances oncological control and preservation of testicular function. Further research, including large-scale prospective studies and long-term follow-ups, is warranted to validate the effectiveness and durability of organ-sparing surgery and to identify optimal patient selection criteria.